Abstract 32P
Background
International guidelines recommend a combination of NK1, 5-HT3 receptor antagonists, and dexamethasone (DEX) as standard antiemetic therapy for patients treated with a doxorubicin and cyclophosphamide (AC) regimen. However, DEX has been associated with several side effects, including diabetes, osteoporosis, and immunosuppression. Additionally, pneumocystis pneumonia, a rare but fatal condition, has been reported, predominantly in patients undergoing the dose-dense AC (ddAC) regimen.
Methods
We recruited 30 patients with Stage I-III breast cancer who received the ddAC regimen. Patients were administered prophylactic olanzapine (OLZ) 5 mg/day on days 1 to 4 in addition to the standard three-drug combination antiemetic regimen, with DEX omitted on days 2 and 3. Nausea/vomiting and drowsiness were evaluated using a 4-point Likert scale questionnaire previously employed in the J-FORCE study, which assessed the efficacy of OLZ 5 mg in high-emetic-risk regimens. The primary endpoint was complete response (CR) rate in the delayed phase (24-120 hours post chemotherapy administration) of the first cycle. Secondary endpoints included the total control (TC) rate of nausea and vomiting, complete control (CC) rate, degree of daytime sleepiness, and quality of life as assessed by EORTC QLQ-C30 Ver.3.
Results
Among the participants, 22 patients (73%) received ddAC as neoadjuvant chemotherapy and 8 (27%) as adjuvant chemotherapy. Median age at the start of treatment was 56 years. CR rates were 73% and 63% in the acute and delayed periods, respectively. TC and CC rates in the acute period were 60% and 73%, whereas those in the delayed period were 36.6% and 63%, respectively. In both periods, 40% of patients experienced moderate or severe sleepiness. Mean scale scores for nausea on the EORTC QLQ-C30 remained within the Minimally Important Difference score level throughout the 4th cycles of treatment.
Conclusions
This prospective pilot study suggests that the addition of OLZ 5mg allows the omission of steroids without a worsening of CINV in patients with ddAC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract